We recently described using neural extra-cellular matrix (ECM) binding Variable Lymphocyte Receptors (VLRs) to target regions of Blood-Brain Barrier (BBB) disruption induced by neuropathologies including glioblastoma (Sci Adv. 2019 May 15;5(5):eaau4245).
